Madrigal Pharmaceuticals (MDGL) Operating Expenses (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Operating Expenses data on file, last reported at $26.8 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $26.8 million, up 494.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $817.8 million (up 19.83% YoY), and the FY2025 annual result was $1.3 billion, up 85.62% from the prior year.
• Operating Expenses slipped to $26.8 million in Q1 2026 per MDGL's latest filing, from $380.7 million in the prior quarter.
• Over five years, Operating Expenses peaked at $675.2 million in Q4 2024 and troughed at $636000.0 in Q2 2024.
• A 5-year average of $139.2 million and a median of $79.4 million in 2022 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Operating Expenses tumbled 99.26% in 2024, then soared 18545.12% in 2025.
• A 5-year view of Operating Expenses shows it stood at $85.3 million in 2022, then jumped by 37.37% to $117.2 million in 2023, then jumped by 476.24% to $675.2 million in 2024, then plunged by 43.62% to $380.7 million in 2025, then sank by 92.95% to $26.8 million in 2026.
• Business Quant data shows MDGL's Operating Expenses at $26.8 million in Q1 2026, $380.7 million in Q4 2025, and $401.2 million in Q3 2025.